France’s Sanofi buys US hemophilia specialist Bioverativ

France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases. The deal announced Monday is the latest such move in a pharmaceutical industry that’s seeing increasing interest in rare diseases.